Safety and efficacy of mitoxantrone liposome combined chemotherapy in the treatment of mixed phenotype acute leukemia
10.3760/cma.j.cn121090-20241210-00554
- VernacularTitle:米托蒽醌脂质体联合化疗方案治疗混合表型急性白血病的安全性及有效性研究
- Author:
Huiwen JIANG
1
;
Cong LU
;
Jing HE
;
Qiuzhe WEI
;
Meifang SU
;
Yaohui WU
;
Junbin HU
Author Information
1. 华中科技大学同济医学院附属协和医院血液病研究所，武汉 430022
- Publication Type:Journal Article
- Keywords:
Mitoxantrone liposome;
Mixed phenotype acute leukemia;
Effectiveness;
Safety
- From:
Chinese Journal of Hematology
2025;46(1):64-69
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety and efficacy of mitoxantrone liposome (MIT-LIP) combined chemotherapy in treating mixed phenotype acute leukemia (MPAL) .Methods:December 2021 to November 2024, MPAL patients who underwent the MAED (MIT-LIP + cytarabine + etoposide + dexamethasone) regimen were retrospectively analyzed. Data on clinical characteristics, adverse reactions, therapeutic outcomes, and long-term prognoses were collected.Results:A total of 7 MPAL patients who received MAED regimen were admitted. Among them, two patients were initially diagnosed with T-ALL or B-ALL, respectively, and transformed into AML after treatment. Three patients were initially diagnosed as MPAL (B/myeloid), one as MPAL (T/myeloid), and one with MPAL (myeloid/plasmacytoid dendritic cell). Among the 7 patients, there were 3 males and 4 females, 1 chromosome abnormalities and 6 gene abnormalities, including 1 case with BCR∷ABL fusion gene. The median age was 38 years (range: 16–58 years). There was no clear related drug allergy and organ toxicity during MAED regimen, and the main adverse effect was hematological toxicity. After induced chemotherapy, all patients achieved complete remission (CR), 2 maintained MRD-negative CR and 1 maintained MRD-positive CR. The other 4 patients underwent allogeneic hematopoietic stem cell transplantation, 2 maintained MRD-negative CR, and 2 relapsed. The current median follow-up time was 12 months, the overall survival (OS) rate was 100%, the relapse-free survival (RFS) rate was 60%, and the median OS time and median RFS time were not reached.Conclusion:The MAED regimen demonstrates high safety and a favorable CR rate in MPAL treatment.
